APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hospital-Acquired Pneumonia (HAP) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hospital-Acquired Pneumonia (HAP) Drugs Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchHospital-Acquired Pneumonia (HAP) Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital-Acquired Pneumonia (HAP) Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hospital-Acquired Pneumonia (HAP) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hospital-Acquired Pneumonia (HAP) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hospital-Acquired Pneumonia (HAP) Drugs market include Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Novartis, Merck, Mylan, Pfizer, AstraZeneca, Theravance Biopharma and The Medicines Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hospital-Acquired Pneumonia (HAP) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hospital-Acquired Pneumonia (HAP) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hospital-Acquired Pneumonia (HAP) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hospital-Acquired Pneumonia (HAP) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Company

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Novartis

Merck

Mylan

Pfizer

AstraZeneca

Theravance Biopharma

The Medicines Company

Shinogi

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Type

Antiviral

Antibacterial

Antifungal

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Application

Hospitals

Clinics

Others

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hospital-Acquired Pneumonia (HAP) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hospital-Acquired Pneumonia (HAP) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hospital-Acquired Pneumonia (HAP) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Hospital-Acquired Pneumonia (HAP) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Pneumonia (HAP) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Pneumonia (HAP) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Pneumonia (HAP) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hospital-Acquired Pneumonia (HAP) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hospital-Acquired Pneumonia (HAP) Drugs industry.

Chapter 3: Detailed analysis of Hospital-Acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hospital-Acquired Pneumonia (HAP) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hospital-Acquired Pneumonia (HAP) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends Table 2. Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers Table 3. Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges Table 4. Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints Table 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Company (2021-2026) Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Hospital-Acquired Pneumonia (HAP) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Company, Product Type & Application Table 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hospital-Acquired Pneumonia (HAP) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antiviral Table 18. Significant Companies of Antibacterial Table 19. Significant Companies of Antifungal Table 20. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type (2021-2026) & (k units) Table 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type (2027-2032) & (k units) Table 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type (2021-2026) Table 29. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Others Table 33. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application (2021-2026) & (k units) Table 35. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application (2027-2032) & (k units) Table 36. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application (2021-2026) Table 42. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application (2027-2032) Table 43. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2021-2026) Table 46. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2027-2032) & (k units) Table 47. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2027-2032) Table 48. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Region (2021-2026) Table 51. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Region (2027-2032) Table 53. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 58. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2026) Table 59. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 60. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2027-2032) Table 61. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Market Share by Country (2027-2032) Table 65. Teva Pharmaceutical Industries Company Information Table 66. Teva Pharmaceutical Industries Business Overview Table 67. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 69. Teva Pharmaceutical Industries Recent Development Table 70. Sun Pharmaceutical Industries Company Information Table 71. Sun Pharmaceutical Industries Business Overview Table 72. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 74. Sun Pharmaceutical Industries Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 79. Novartis Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 84. Merck Recent Development Table 85. Mylan Company Information Table 86. Mylan Business Overview Table 87. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 89. Mylan Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 94. Pfizer Recent Development Table 95. AstraZeneca Company Information Table 96. AstraZeneca Business Overview Table 97. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 99. AstraZeneca Recent Development Table 100. Theravance Biopharma Company Information Table 101. Theravance Biopharma Business Overview Table 102. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 104. Theravance Biopharma Recent Development Table 105. The Medicines Company Company Information Table 106. The Medicines Company Business Overview Table 107. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 109. The Medicines Company Recent Development Table 110. Shinogi Company Information Table 111. Shinogi Business Overview Table 112. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 114. Shinogi Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List Table 118. Hospital-Acquired Pneumonia (HAP) Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Hospital-Acquired Pneumonia (HAP) Drugs Product Image Figure 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (2021-2032) & (k units) Figure 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antiviral Image Figure 10. Antibacterial Image Figure 11. Antifungal Image Figure 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Hospital-Acquired Pneumonia (HAP) Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Novartis
  • Merck
  • Mylan
  • Pfizer
  • AstraZeneca
  • Theravance Biopharma
  • The Medicines Company
  • Shinogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hospital-Acquired Pneumonia (HAP) Drugs Market Dynamics
  1. 2.1 Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends
  2. 2.2 Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers
  3. 2.3 Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges
  4. 2.4 Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints
3 Hospital-Acquired Pneumonia (HAP) Drugs Market by Company
  1. 3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Hospital-Acquired Pneumonia (HAP) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Hospital-Acquired Pneumonia (HAP) Drugs Company Product Type and Application
  8. 3.8 Global Hospital-Acquired Pneumonia (HAP) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hospital-Acquired Pneumonia (HAP) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hospital-Acquired Pneumonia (HAP) Drugs Market by Type
  1. 4.1 Hospital-Acquired Pneumonia (HAP) Drugs Type Introduction
  2. 4.1.1 Antiviral
  3. 4.1.2 Antibacterial
  4. 4.1.3 Antifungal
  5. 4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type
  6. 4.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type
  10. 4.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type (2021-2032)
5 Hospital-Acquired Pneumonia (HAP) Drugs Market by Application
  1. 5.1 Hospital-Acquired Pneumonia (HAP) Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application
  6. 5.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application
  10. 5.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application (2021-2032)
6 Hospital-Acquired Pneumonia (HAP) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Country, 2025 VS 2032
7 Hospital-Acquired Pneumonia (HAP) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries
  2. 8.1.1 Teva Pharmaceutical Industries Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 8.2 Sun Pharmaceutical Industries
  8. 8.2.1 Sun Pharmaceutical Industries Company Information
  9. 8.2.2 Sun Pharmaceutical Industries Business Overview
  10. 8.2.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Industries Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Theravance Biopharma
  44. 8.8.1 Theravance Biopharma Company Information
  45. 8.8.2 Theravance Biopharma Business Overview
  46. 8.8.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  48. 8.8.5 Theravance Biopharma Recent Developments
  49. 8.9 The Medicines Company
  50. 8.9.1 The Medicines Company Company Information
  51. 8.9.2 The Medicines Company Business Overview
  52. 8.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  54. 8.9.5 The Medicines Company Recent Developments
  55. 8.10 Shinogi
  56. 8.10.1 Shinogi Company Information
  57. 8.10.2 Shinogi Business Overview
  58. 8.10.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  60. 8.10.5 Shinogi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Analysis
  2. 9.1.1 Hospital-Acquired Pneumonia (HAP) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hospital-Acquired Pneumonia (HAP) Drugs Sales Mode & Process
  6. 9.2 Hospital-Acquired Pneumonia (HAP) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Distributors
  9. 9.2.3 Hospital-Acquired Pneumonia (HAP) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst